Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) SVP Yakob Liawatidewi Sells 5,000 Shares of Stock

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) SVP Yakob Liawatidewi sold 5,000 shares of the firm’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $20.73, for a total value of $103,650.00. Following the completion of the sale, the senior vice president now owns 47,188 shares in the company, valued at $978,207.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ AMPH traded down $0.02 during midday trading on Thursday, reaching $20.83. 5,172 shares of the company traded hands, compared to its average volume of 166,120. Amphastar Pharmaceuticals Inc has a 52 week low of $17.25 and a 52 week high of $25.43. The stock’s 50-day moving average is $20.24. The company has a current ratio of 2.81, a quick ratio of 1.83 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $995.14 million, a P/E ratio of 100.38 and a beta of 1.35.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.05. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. The business had revenue of $79.00 million for the quarter, compared to analysts’ expectations of $78.90 million. During the same period in the previous year, the business earned $0.03 earnings per share. The company’s revenue was up 11.3% on a year-over-year basis. As a group, equities analysts anticipate that Amphastar Pharmaceuticals Inc will post 0.15 earnings per share for the current fiscal year.



A number of equities research analysts have issued reports on the company. BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research note on Wednesday, July 10th. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, August 7th. Finally, Wells Fargo & Co set a $29.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 6th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $24.64.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Financial Gravity Wealth Inc. bought a new stake in shares of Amphastar Pharmaceuticals during the first quarter valued at about $43,000. Quadrant Capital Group LLC acquired a new position in Amphastar Pharmaceuticals during the first quarter worth about $53,000. Acadian Asset Management LLC acquired a new position in Amphastar Pharmaceuticals during the second quarter worth about $88,000. Bank of Montreal Can grew its holdings in Amphastar Pharmaceuticals by 130.7% during the second quarter. Bank of Montreal Can now owns 4,923 shares of the company’s stock worth $104,000 after acquiring an additional 2,789 shares during the period. Finally, BNP Paribas Arbitrage SA grew its holdings in Amphastar Pharmaceuticals by 52,407.1% during the first quarter. BNP Paribas Arbitrage SA now owns 7,351 shares of the company’s stock worth $150,000 after acquiring an additional 7,337 shares during the period. Institutional investors and hedge funds own 47.61% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Read More: What factors cause inflation to rise?

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.